X
KEY SERVICES
Details:
Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Amantadine HCl-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Upsher-Smith Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 01, 2024
Details:
Through the acquisition, Bora gains Upsher-Smith’s product portfolio, including Amantadine hydrochloride, indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.
Lead Product(s): Amantadine Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Amantadine HCl-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Upsher-Smith Laboratories
Deal Size: $210.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 18, 2024
Details:
Under the partnership, Bora will manufacture and commercialize a range of oral dosage form drugs (OSD), including CT-G20, a hypertrophic cardiomyopathy treatment candidate, across the APAC region.
Lead Product(s): CT-G20
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CT-G20
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Celltrion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 06, 2023
Details:
CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific factors.
Lead Product(s): Foslinanib,Sorafenib
Therapeutic Area: Oncology Product Name: CVM-1118
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TaiRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 27, 2022
Details:
Initially, Bora will manufacture Phexxi for nations currently considering formal regulatory approval of Phexxi (L-lactic Acid), for the prevention of pregnancy, including Mexico and Nigeria.
Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Phexxi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Evofem Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 10, 2022
Details:
Upon PMDA’s approval, Bora will be the commercial manufacturing site for the generic product production. Bora Pharmaceuticals’ sites already have an excellent track record with many regulatory agencies around the world.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Kyowa Pharmaceutical Industry
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 05, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Bora Pharmaceuticals- Making success more certain.
